Welcome to our dedicated page for MDB Capital Holdings LLC-A news (Ticker: MDBH), a resource for investors and traders seeking the latest updates and insights on MDB Capital Holdings LLC-A stock.
MDB Capital Holdings, LLC (NASDAQ: MDBH) is an investment holding company and public venture platform in the investment banking and securities dealing industry. News and press releases about MDB Capital highlight its focus on launching early-stage and disruptive "Big Idea" companies through public venture capital, as well as developments across its subsidiaries such as MDB Capital and PatentVest.
Readers following MDBH news can expect updates on private placements, initial public offerings, and post-IPO offerings for emerging companies that align with MDB’s investment criteria. Recent announcements describe offerings and planned offerings for companies in areas such as biopharmaceuticals and consumer products, along with the expansion of MDB’s pipeline of early-stage, disruptive companies and partnerships with investor groups and registered investment advisers.
News related to PatentVest, a division of MDB Capital Holdings, features IP-focused research and strategy. PatentVest issues PatentVest Pulse reports that analyze intellectual property and competitive landscapes in sectors including quantum computing, the space economy, and cardiac diagnostics. These reports use patent data to examine leadership, defensible IP positions, and commercialization progress across innovation-driven markets.
Additional MDBH news items cover conference presentations, investor webinars, and corporate updates, including plans to spin out PatentVest as an independent public company. For investors and observers, the MDBH news feed provides insight into the company’s ongoing financings, its role in public venture capital, and its IP-centered analysis of emerging technology markets.
ClearSign Technologies Corporation (CLIR) announced significant changes to its Board of Directors. The Board expanded from five to seven directors with the appointment of Anthony DiGiandomenico and Lou Basenese, effective May 22, 2025. Additionally, David M. Maley will not seek re-election at the 2025 annual stockholders meeting.
DiGiandomenico, co-founder and Chief of Transactions at MDB Capital Holdings, brings extensive experience in early-stage disruptive technologies. Basenese, currently Executive VP of Market Strategy at Prairie Operating Co. and CEO of The Basenese Group, contributes over 25 years of experience in equity research, investment banking, and strategic planning.
MDB Capital Holdings (NASDAQ: MDBH), a public venture platform specializing in launching disruptive technology companies, has released its Q1 2025 operational update. Key highlights include: successfully closing an $11.5 million public offering for HeartBeam (NASDAQ: BEAT), securing LOIs for 3 new "Big Idea" companies, and growing their MDB Direct accounts by 26% with 111 new additions. The company reported a 4.5% increase in its shareholder base during Q1 2025.
The company is expanding its relationships with angel groups, RIAs, and family offices while exploring new ways to leverage its self-clearing platform. MDB has also implemented a revised executive compensation plan for four top executives to better align with shareholder interests. CEO Christopher Marlett noted continued interest from micro-cap companies seeking to go public despite market volatility.
MDB Capital Holdings (NASDAQ: MDBH), a public venture platform specializing in launching disruptive technology companies, has announced its upcoming first quarter 2025 earnings conference call. The Zoom webinar is scheduled for Wednesday, May 21, 2025, at 4:30 p.m. Eastern Time.
CEO and Co-Founder Christopher Marlett will lead the presentation, accompanied by other management team members. The discussion will cover Q1 2025 results, recent developments, ongoing initiatives, and future milestones. The company will release its detailed financial results before the call. Investors can access the webinar through pre-registration or MDB's investor relations website.
PatentVest has released a comprehensive report on the brain-computer interface (BCI) market, projected to exceed $400 billion in the US. The report analyzes over 2,160 patent families across 664 entities in the neurotechnology sector.
The market comprises $80 billion in high-acuity, early-adopting patient populations and $320 billion in potential long-term applications for neurological and psychiatric conditions. While Neuralink maintains high visibility, Synchron is establishing category leadership through minimally invasive platforms and targeted IP strategy across 10 jurisdictions.
The report highlights key players including INBRAIN, Blackrock, Precision Neuroscience, and Paradromics, who are securing market positions through differentiated technologies and IP consolidation. Academic institutions like Tianjin University, Stanford, and the University of California continue to hold foundational patents in neural signal processing and interface architecture.
MDB Capital Holdings (NASDAQ: MDBH) has released its Q4 and full-year 2024 update, highlighting significant operational achievements in the public venture platform space. Key accomplishments include:
- Successfully launched eXoZymes Inc (EXOZ) through IPO, maintaining ~47% ownership
- Expanded analyst team to 14 members, screening 8,964 companies and deeply examining 217 potential market leaders
- Grew shareholder base by 12% with 456 new brokerage accounts
- Increased assets under management from $2M to $44M
- Launched first self-clearing broker-dealer platform for public venture investing
- Expanded PatentVest client base from 3 to 8 clients
The company filed its Form 10-K on March 31, including consolidated financial results through November 14, 2024, when eXoZymes was deconsolidated following its IPO.
MDB Capital Holdings (NASDAQ: MDBH), a public venture platform specializing in deep technology companies, has scheduled a Zoom webinar to discuss its Q4 and full year 2024 financial results on Monday, March 31, 2025, at 4:30 p.m. Eastern Time.
The earnings conference call will be led by CEO and Co-Founder Christopher Marlett, along with other management team members. They will review recent developments, ongoing initiatives, and anticipated milestones, followed by a Q&A session. The company will release detailed financial results before the call.
Investors can access the webinar through pre-registration or via MDB's investor relations website at https://investors.mdb.com/.
PatentVest has released a new Pulse Report analyzing the AI data center patent landscape, revealing China's dominance with 77% of global patent filings. The report highlights that five of the top patent holders are Chinese companies.
The data center as a service market, valued at $71.92 billion in 2022, is projected to reach $431.43 billion by 2030. This growth is driven by increasing demand for AI-optimized infrastructure and energy-efficient computing innovations.
Key market factors include:
- Technology innovations in AI-specific chip architectures and cooling systems
- Surge in patent filings for foundational technologies
- Significant patent litigation cases, including Intel's $2.18 billion ruling and Netlist's $118 million lawsuit against Samsung
Enterprise data generation is expected to reach 1.2 million exabytes by 2025, driving the need for advanced AI infrastructure solutions focusing on high-performance computing and real-time data processing.
eXoZymes (Nasdaq: EXOZ), a company specializing in AI-engineered enzymes for transforming sustainable feedstock into chemicals, medicines, and biofuels, announced that CEO Michael Heltzen and team members will ring the Nasdaq closing bell on February 19, 2025. This ceremony commemorates their successful IPO, which closed on November 14, 2024, with shares priced at $8 per share.
The bell ringing ceremony will be broadcast live at 3:50 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York City. The company views this milestone as a marker of transition into what they call the 'exozymes era of biotechnology,' following the synthetic biology era.